Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

• Jahresbericht (10-K)

  Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.

  Eingereicht am 2026-02-11

  Dokument ansehen

• Quartalsbericht (10-Q)

  Ein Update zur finanziellen Entwicklung der letzten drei Monate.

  Eingereicht am 2026-07-29

  Dokument ansehen

• Ad-hoc-Meldung (8-K)

  Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.

  Eingereicht am 2026-09-28

  Dokument ansehen

• 9d agoPOSITIVE
  Le azioni di Viking Therapeutics possono mantenere i guadagni di oggi?

  Viking Therapeutics Inc. (VKTX) shares surged following the release of promising Phase 2 clinical trial data for its lead weight-loss drug candidate, VK2735. The new top-line results indicate that patients can reduce dosing frequency without sacrificing significant weight loss progress. This development is a key catalyst for the volatile VKTX stock, which is now up nearly 10% year-to-date, though still down from its July peak. The positive data suggests potential for improved patient compliance and market adoption, bolstering investor confidence in the company's pipeline.

• 3/16/2026POSITIVE
  What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment

  Viking Therapeutics, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, has secured a $7 million investment. This funding is expected to accelerate the development of its pipeline therapies, which target significant unmet medical needs in obesity and related conditions. The investment signals strong confidence from investors in Viking's technology and therapeutic approach, potentially paving the way for further clinical advancements and future commercialization. For shareholders, this capital injection is a positive development, enhancing the company's financial stability and its capacity to reach key development milestones.

• 3/11/2026POSITIVE
  Here's Why Viking Therapeutics Stock Recovered and Can Soar in 2026

  Viking Therapeutics is advancing its lead drug candidate through a Phase 3 trial, with investors anticipating significant data by the end of September. This pivotal trial, if successful, could validate the drug's efficacy and safety, paving the way for regulatory approval and commercialization. The potential for positive data readouts fuels optimism for the stock's performance, with analysts suggesting a potential surge in 2026. Investors are closely monitoring the trial's progress as a key catalyst for future growth and shareholder value.

• 2/24/2026POSITIVE
  Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.

  Viking Therapeutics is emerging as a potential high-reward bet in the booming weight-loss drug market. The article frames it as a "moon shot," suggesting explosive, albeit speculative, growth potential. For investors looking to capitalize on the pharmaceutical sector's "gold rush," Viking presents an intriguing alternative to established giants like Novo Nordisk and Eli Lilly. While the investment carries significant risk, the success of its drug candidates could translate into exceptional returns. The analysis suggests that with appropriate risk capital, investing in Viking Therapeutics could be a strategy to gain significant exposure to one of the most profitable market trends today, positioning it as a long-term growth opportunity.

• 2/23/2026POSITIVE
  Viking Therapeutics Stock Gains Amid Obesity Drug Buzz

  Shares of Viking Therapeutics (VKTX) are experiencing a significant surge, catalyzed by news from the competitive obesity drug sector. The momentum stems from data from Novo Nordisk's REDEFINE 4 trial, which suggests its new drug trails Eli Lilly's tirzepatide in weight loss efficacy. This perceived weakness from a key competitor is fueling investor optimism about the potential of Viking's own drug candidate. The market is betting that Viking's product could emerge as a 'best-in-class' solution, capturing substantial market share in a multi-billion dollar therapeutic area. The stock's reaction highlights how sensitive biotech valuations are to competitors' clinical data.

• 2/23/2026POSITIVE
  Why Viking Therapeutics Stock Is Up More Than 9% Today

  Shares of Viking Therapeutics (VKTX) surged by more than 9% in today's trading session, fueled by favorable competitive news. A potential rival weight-loss drug has suffered a major setback, a development that significantly improves the outlook for Viking's own leading candidate, VK2735, which is currently in phase 3 trials. This development is crucial as it lessens the competitive pressure in the highly lucrative and crowded market for anti-obesity treatments. Investors reacted with optimism, pricing in a potentially smoother path to commercialization and a larger market share for VK2735. The news bolsters confidence in Viking's potential to become a key player in this fast-growing therapeutic area, with direct implications for the company's future revenue streams.